Beta-Blockers and Bone Health
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Sponsor Protocol Number: 14-009604
About this study
The proposed study will directly examine whether bone mineral density (BMD) and bone microstructure are better preserved among HF patients on chronic β-blockers and account for the reports of decreased fracture.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Olmsted County residents
- Age ≥50 yrs
- History of HF diagnoses and either:
- have been on β-blockers for at least 1 year
- have not received chronic β-blockers for at least the past 3 years
- Age and sex matched controls who do not have HF and who have not received chronic β-blockers for the past 3 years
- Eligible women will be postmenopausal for at least 1 year
Exclusion Criteria:
- Current or past history of malignancy that has required chemotherapy
- Chronic renal insufficiency (GFR<30)
- Bilateral hip replacements/pinning
- History of current or past chronic glucocorticoid use (>3 months)
- On pharmacologic doses of thyroid replacement
- Current users of teraparatide, denosumab, oral or IV bisphosphonates, calcitonin, oral hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), aromatase inhibitors in past 12 months, or androgen blockers
- Subjects who are not ambulatory
More information
Publications
Publications are currently not available